Methods: p-SCN-NOTA was conjugated to 8-aminooctanoic acid (Aoc)-BN(7-14) in solution to yield NOTA-Bn-SCN-Aoc-BN(7-14). The unlabeled peptide was evaluated SIS3 mouse in a cell binding assay using PC-3 prostate cancer cells and

I-125-Tyr(4)-BN to determine the IC50 value. The peptide was radiolabeled with Cu-64 and evaluated for internalization into PC-3 cells and for tumor uptake in mice bearing PC-3 xenografts using biodistribution and micro-positron emission tomography imaging studies.

Results: The binding assay demonstrated that NOTA-Bn-SCN-Aoc-BN(7-14) bound with high affinity to GRPR with an IC50 of 1.4 nM. The radiolabeled peptide demonstrated time-dependent internalization into PC-3 cells. In vivo, the peptide demonstrated tumor-specific uptake and imaging that were comparable to those of previously reported Cu-64-labeled BN analogues.

Conclusions: These studies demonstrate that Cu-64-NOTA-Bn-SCN-Aoc-BN(7-14) binds to GRPR-expressing cells and that it can be used for imaging of GRPR-expressing prostate cancer. (C) 2012 Elsevier Inc. All rights reserved.”
“Objective(s): Anatomic repair for congenitally corrected transposition

of the great arteries (ccTGA) has been shown to improve patient survival. We sought to examine long-term outcomes in patients after anatomic repair with focus on results in high-risk patients, the fate DZNeP cell line of the neo-aortic valve, and occurrence of morphologically left ventricular dysfunction.

Methods: We conducted a retrospective, single-institution study of patients undergoing anatomic repair for ccTGA. A total of 113 patients from 1991 to March 2011 were included. Double-switch (DS) repair was performed in 68 patients, with Rastelli-Senning

(RS)-type repair in 45. Pulmonary artery banding for retraining was performed in 23 cases. Patients were followed up for survival status, morbidity, and reinterventions. A subgroup of 17 high-risk patients in severe heart failure, ventilated, and on inotropes before repair, were included.

Results: Median age at repair was 3.2 years (range, 25 days to 40 years) and weight was 14.3 kg (3.2-61.4). There were 5 (of 68; 7.4%) early deaths in the DS group and 0 (of 45) in the RS group. Actuarial survivals in the DS group were 87.6%, 83.9%, 83.9% Glutamate dehydrogenase at 1, 5, and 10 years versus 91.6%, 91.6%, 77.3% in the RS group (log-rank: P = .98). Freedom from death, transplantation, or heart failure was significantly better in the RS group at 10 years (P = .03). There was no difference in reintervention at 10 years (DS, 50.3%; RS, 49.1%; P = .44). In the DS group, the Lecompte maneuver was associated with late reinterventions on the pulmonary arteries. Overall survival in the high-risk group was 70.6%. During follow-up, 14.2% patients had poor function of the morphologically left ventricle, all in the DS group, but this was not related to preoperative status or previous banding.